The bill codifies definitions of product hopping and patent thicketing within the Federal Trade Commission (FTC) statute, allowing the FTC to challenge these practices as anticompetitive and to enable the FTC to bring antitrust suits against drug companies.
A bipartisan bill to give the Federal Trade Commission (FTC) the authority to bring antitrust suits against pharmaceutical companies for blocking competition through use of the US patent system was introduced in the Senate this month.
The bill, called the Affordable Prescriptions for Patients Act, was introduced by Senator John Cornyn, R-Texas, and Richard Blumenthal, D-Connecticut, a few days after the Judiciary committee, on which both lawmakers sit, held a hearing about intellectual property, patent law, and the impact on drug prices.
According to a statement from both of the senators’ offices, the act would curtail drug companies’ use of patents to protect branded prescription drugs and prevent generic and biosimilar competition from coming to market.
The bill codifies definitions of product hopping and patent thicketing within the FTC statute, allowing the FTC to challenge these practices as anticompetitive and to enable the FTC to bring antitrust suits against drug companies.
Product hopping involves making slight alterations that hold no significant therapeutic value to an existing drug and patenting the resulting product as though it were a new drug. The change is typically made right before the original version of the drug is slated to lose patent protection.
Patent thickets, such as in the case of AbbVie’s Humira, force biosimilar competitors to wage costly court fights if they want to attempt to enter the market. This week, in fact, AbbVie settled its patent litigation with Boehringer Ingelheim (BI) over adalimumab. BI had alleged that a patent thicket for Humira had hindered its ability to bring its biosimilar to market. Now, under the terms of the settlement, BI’s biosimilar, Cyltezo, will not enter the US market until July 1, 2023.
Under the proposed legislation, manufacturers will be allowed to argue that their actions are not anticompetitive by submitting evidence to show the additional patents provide clinically meaningful and significant therapeutic or safety benefits; significantly improved product purity or potency; significant gained efficiencies in manufacturing; or other improved product attributes having substantial benefits for consumers or patients. Manufacturers can also claim that a generic or biosimilar could still make it to market without including the improvements claimed in additional patents. Manufacturers would have to submit all costs related to the original drug, including research and development, manufacturing, and marketing.
“Drug companies have taken advantage of the patent system to maintain their monopoly on certain drugs and prevent generics from coming to market,” Cornyn said. “These tactics mean Americans are forced to pay more for the life-saving medications they need. This bill puts patients first and reforms the system to encourage the availability of cheaper generics.”
“Using practices that would make the robber barons of the gilded age blush, Big Pharma has crushed competition and stifled access to cheaper generic drugs to squeeze billions out of families, businesses, and the government,” Blumenthal said. “Through common sense reforms, this bipartisan bill will empower the FTC to fight back against drug companies’ most egregious and monopolistic practices. It represents an important step in reining in Big Pharma’s greed and puts the industry on notice—enough is enough.”
The Affordable Prescriptions for Patients Act is supported by Patients for Affordable Drugs, Coalition for Affordable Prescription Drugs, Campaign for Sustainable Rx Pricing, Vizient, Prime Therapeutics, and biosimilar developer Mylan.
Higher-Cost Therapies for ARMD Could Contribute to Heightened Medicare Costs; Biosimilars Could Help
September 24th 2023Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (ARMD) that could increase Medicare, but biosimilars could help.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward
September 20th 2023In the final part of a 3-part series, Sarfaraz K. Niazi, PhD, gives his take on the FDA's recent workshop dedicated to streamlining biosimilar development and his opinion on what the industry can learn from the webinar presenters.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development
September 13th 2023An FDA workshop featuring regulators from around the world provided the regulatory perspective on how each government determines whether a biosimilar is clinically equivalent to their reference product, highlighting the science behind their development guidelines.
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
September 7th 2023Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.
2 Clarke Drive
Cranbury, NJ 08512